DeutschNewstral
Article
bizjournals.com on 2018-08-28 23:54
East Bay biotech nets Stanford spinout to figure out what turns genes off, on
Related news
- Stanford biotech spinout snares $100M round on path toward IPObizjournals.com
- Going from Stanford spinout to IPO in 14 months, gene-editing biotech seeks $100Mbizjournals.com
- How this Stanford biotech spinout plans to quickly boost gene therapybizjournals.com
- Stanford cancer spinout lands big biotech dealbizjournals.com
- Stanford spinout Snorkel AI is Silicon Valley's newest unicornbizjournals.com
- SStanford graduates discuss experience growing biotech startupstanforddaily.com
- Stanford spinout says its AI-powered machines are the future of industrial robotsbizjournals.com
- After AI drug discovery pact with Genentech, Stanford spinout lines up $52M Series A roundbizjournals.com
- Investors pile on Stanford spinout promising new ways to attack cancer, autoimmune diseasesbizjournals.com
- Stanford spinout DiCE rolls out with potential $2.2 billion Sanofi dealbizjournals.com
- Stanford, Harvard geneticists launch biotech to fight deadly bacteriabizjournals.com
- Harvard, Stanford geneticists launch biotech to fight deadly bacteriabizjournals.com
- East Bay biotech nets potential $1 billion Crohn's drug dealbizjournals.com
- Pitt biotech spinout raises $3Mbizjournals.com
- DRandolph nets 17 in Arizona's 75-70 win over Stanforddcourier.com